In conclusion, comparative clinical studies with tacrolimus in heart recipients tend to show a similar or increased diabetogenic potential compared with cyclosporine-ME-based therapy. However, these changes are often accompanied by a reduced effect on lipid metabolism and hypertension suggesting a superior cardiovascular risk profile. The superior control of acute rejection also positions tacrolimus as an attractive alternative to cyclosporine for heart recipients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
heart recipients
12
post-transplant diabetes
4
diabetes mellitus
4
mellitus ptdm
4
ptdm heart
4
recipients conclusion
4
conclusion comparative
4
comparative clinical
4
clinical studies
4
studies tacrolimus
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!